SEC Tracker
Get the app

Tectonic Therapeutic TECX

Tectonic Therapeutic Q3 FY24: net loss $17.7M; diluted EPS −$2.26

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Tectonic Therapeutic reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$17.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$2.26No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$1.2010-Q income statement, on EDGAR
  3. Cash and cash equivalents$159.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$19.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Tectonic Therapeutic files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  2. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  5. Annexon ANNX public float $244M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.